Hospital
Henry County Memorial Hospital
Henry County Memorial Hospital was paid $11.51M by Medicaid between Jan 2018 and Nov 2024, across 135 billing codes. Its largest line is 99284, emergency room visit (serious) — 27% of everything it billed.
33Billing provider infoHENRY COUNTY MEMORIAL HOSPITAL
NEW CASTLE, IN 47362
NEW CASTLE, IN 47362
33aNPI1356428429assigned 11/01/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.51M
24GClaims358,737
24DCodes billed135
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#31 of 69
Median peer was paid$9.76M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RING, BRIAN controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,092 | $537K | |
| 2019 | 41,858 | $1.13M | |
| 2020 | 42,188 | $1.29M | |
| 2021 | 52,220 | $1.69M | |
| 2022 | 67,172 | $2.68M | |
| 2023 | 62,882 | $2.34M | |
| 2024incomplete | 46,325 | $1.84M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 22,734 | 17,201 | $3.13M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 23,791 | 19,181 | $3.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 12,129 | 9,008 | $1.36M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.3% | 12,314 | 9,211 | $608K |
| 71045 | Radiologic examination, chest; single view | 5.0% | 5,468 | 4,054 | $573K |
| 59025 | Fetal non-stress test | 3.8% | 1,750 | 1,034 | $433K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 6,926 | 4,821 | $189K |
| 80053 | Comprehensive metabolic panel | 1.3% | 32,611 | 24,615 | $154K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 39,511 | 29,127 | $136K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 72,985 | 54,015 | $135K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,511 | 1,063 | $103K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,522 | 1,197 | $101K |
123 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 645 | $96K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,151 | $93K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 910 | $91K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,541 | $79K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,360 | $78K |
| 80074 | <1% | 2,059 | $74K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,527 | $71K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,592 | $67K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,324 | $65K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,269 | $63K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 587 | $56K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 166 | $54K |
| 62323 | <1% | 69 | $52K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 113 | $48K |
| 80061 | Lipid panel | <1% | 7,777 | $47K |
| 80081 | <1% | 679 | $37K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,081 | $36K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 602 | $32K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 367 | $24K |
| 84484 | <1% | 4,600 | $23K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,104 | $23K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,264 | $23K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,438 | $21K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 559 | $21K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,273 | $20K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,792 | $20K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 580 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,599 | $16K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 292 | $15K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,339 | $14K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 439 | $13K |
| 81001 | <1% | 8,596 | $13K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 189 | $12K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 631 | $12K |
| 82607 | <1% | 1,395 | $10K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 641 | $9K |
| 0240U | <1% | 111 | $9K | |
| 83690 | <1% | 2,823 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 645 | $8K |
| 81025 | <1% | 1,509 | $8K | |
| 80361 | <1% | 596 | $8K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 87 | $7K |
| 94010 | <1% | 127 | $5K | |
| 80069 | <1% | 1,800 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,559 | $5K |
| 73130 | <1% | 157 | $4K | |
| 52204 | <1% | 14 | $4K | |
| 88142 | <1% | 492 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 135 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 118 | $3K |
| 85610 | <1% | 2,214 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 114 | $3K |
| 80050 | General health panel | <1% | 13 | $3K |
| 83735 | <1% | 764 | $2K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 161 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 138 | $2K |
| 64721 | <1% | 20 | $2K | |
| 82728 | <1% | 282 | $2K | |
| 73110 | <1% | 39 | $2K | |
| 86592 | <1% | 606 | $2K | |
| 83550 | <1% | 327 | $1K | |
| 84439 | <1% | 200 | $1K | |
| 83880 | <1% | 120 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 55 | $1K |
| 83540 | <1% | 330 | $984.13 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 14 | $945.12 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 19 | $883.83 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 147 | $772.67 |
| 85027 | <1% | 383 | $706.88 | |
| 84702 | <1% | 82 | $676.59 | |
| 73562 | <1% | 38 | $673.52 | |
| 84156 | <1% | 209 | $590.25 | |
| 83615 | <1% | 129 | $586.28 | |
| 82950 | <1% | 223 | $569.56 | |
| 82550 | <1% | 195 | $532.03 | |
| 76775 | <1% | 34 | $490.07 | |
| 87081 | <1% | 100 | $484.13 | |
| 84550 | <1% | 143 | $477.48 | |
| 87650 | <1% | 30 | $454.34 | |
| 82570 | <1% | 105 | $443.85 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 68 | $435.63 |
| 82746 | <1% | 66 | $417.01 | |
| 82043 | <1% | 154 | $408.75 | |
| 81003 | <1% | 374 | $406.74 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 1,156 | $327.11 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,819 | $323.50 |
| 86850 | <1% | 115 | $302.37 | |
| 84703 | <1% | 56 | $300.80 | |
| 77077 | <1% | 18 | $234.28 | |
| 80305 | <1% | 30 | $188.74 | |
| 85379 | <1% | 59 | $142.52 | |
| 99001 | <1% | 13 | $115.19 | |
| 87186 | <1% | 15 | $69.72 | |
| 86703 | <1% | 12 | $65.64 | |
| 82565 | <1% | 34 | $22.70 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 26 | $21.06 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,182 | $10.29 |
| 82962 | <1% | 19 | $6.18 | |
| 86140 | <1% | 26 | $5.02 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 995 | $4.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,077 | $3.30 |
| 90686 | <1% | 12 | $0.09 | |
| J2704 | Injection, propofol, 10 mg | 0% | 2,291 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 657 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 1,791 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 596 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 282 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 884 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 21 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 154 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 188 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 82 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 14 | $0.00 |
| 96376 | 0% | 20 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 16 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 41 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 2,977 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 130 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 522 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 321 | $0.00 |
| 0353U | 0% | 148 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 35 | $0.00 |
| 64417 | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRING, BRIAN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Henry County Memorial Hospital | New Castle, IN | $10.42M |
| Henry County Memorial Hospital | New Castle, IN | $2.23M |
| New Castle Clinic INC | New Castle, IN | $1.39M |
| Henry County Memorial Hospital | New Castle, IN | $499K |
| Henry County Memorial Hospital | New Castle, IN | $453K |
| Henry County Memorial Hospital | Cambridge City, IN | $360K |
| New Castle Clinic INC | New Castle, IN | $68K |
| Henry County Memorial Hospital | New Castle, IN | $17K |
| Henry County Memorial Hospital | Middletown, IN | $7K |
| Henry County Memorial Hospital | Greenfield, IN | $4K |
| Henry County Memorial Hospital | New Castle, IN | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.